# Natalizumab De-escalation With Interferon Beta-1b

> **NCT01144052** · PHASE4 · COMPLETED · sponsor: **Claudio Gobbi** · enrollment: 19 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** interferon beta-1b
- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT01144052
- **Lead sponsor:** Claudio Gobbi
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2014-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01144052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01144052, "Natalizumab De-escalation With Interferon Beta-1b". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01144052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*